Tofacitinib for the treatment of active ankylosing spondylitis in adults

Raagav Mohanakrishnan, Secia Beier, Atul Deodhar

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Introduction: Ankylosing spondylitis, also known as radiographic axial spondyloarthritis, is a complex, immune-mediated inflammatory disorder most commonly involving the spine including the sacroiliac joints. Areas Covered: Complex pathogenesis of axial spondyloarthritis involving genetic, environmental, and both innate and adaptive immune systems. Treatment options for ankylosing spondylitis. Pharmacologic properties, efficacy, and safety of tofacitinib, a JAK inhibitor. Data regarding efficacy of approved JAK inhibitors in the treatment of ankylosing spondylitis, including tofacitinib, upadacitinib, and filgotinib. Expert opinion: Current treatment options of ankylosing spondylitis include NSAIDs, TNFi, and IL-17i. JAK inhibitors present a new class of therapy that has shown efficacy in the treatment of active ankylosing spondylitis in adults. While it has not been directly compared to alternative therapies, tofacitinib has been shown to be effective in both phase II and phase III trials for the treatment of ankylosing spondylitis. While these trials did not show any significant difference from placebo in terms of safety, the ORAL Surveillance study showed tofacitinib to be inferior to TNFi when comparing adverse events. Thus, tofacitinib presents a viable treatment option for the management of AS, however shared decision-making regarding risks and benefits will be important.

Original languageEnglish (US)
Pages (from-to)273-280
Number of pages8
JournalExpert Review of Clinical Immunology
Volume18
Issue number3
DOIs
StatePublished - 2022

Keywords

  • Ankylosing spondylitis
  • JAK
  • JAK-inhibitor
  • axial spondyloarthritis
  • spondyloarthritis
  • tofacitinib

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint

Dive into the research topics of 'Tofacitinib for the treatment of active ankylosing spondylitis in adults'. Together they form a unique fingerprint.

Cite this